Drug-resistant tuberculosis treatment

(no
 
change)
Clavulanic acid should not be included in the tr
eatment o
f MDR/
RR-TB patients on longer r
egimens
 (str
ong r
ecommendation 
against use, low cer
tainty in the estimates o
f effect)
.
70
3.14 Clavulanic acid should not be included in the tr
eatment o
f MDR/RR-TB 
patients on longer
regimens.
(Str
ong r
ecommendation against use, low cer
tainty in the estimates o
f effect). 
(no
 
change)
70
Imipenem–cilastatin and mer
openem ar
e administer
ed with clavulanic acid, which is available only in for
mulations combined with amo
xicillin (amo
xicillin–clavulanic 
acid). When included, clavulanic acid is not 
counted as an additional effective TB agent and should not be used without imipenem–cilastatin or
mer
openem.

---

Supplementary Table
94
Recommendations in the 2019 updat
e
Recommendations in the curr
ent updat
e
Section 3: The duration o
f longer MDR-TB r
egimens
 
Section 3: Longer r
egimens for multidrug-/ rifampicin-r
esistant 
tuber
culosis
In MDR/RR-TB patients on longer r
egimens, a total tr
eatment 
duration o
f 18–20 months is suggested for most patients; the 
duration may be modified accor
ding to the patient’
s r
esponse to 
therapy
 (conditional r
ecommendation, ver
y low cer
tainty in the 
estimates o
f
 
effect).
3.15 In MDR/RR-TB patients on longer r
egimens, a total tr
eatment duration o
f 
18–20 months is suggested for most patients; the duration may be modified accor
ding to the patient’
s r
esponse to
therapy
. 
(Conditional r
ecommendation, ver
y low cer
tainty in the estimates o
f effect).